

# CRTH2-IN-1

Catalog No: tcsc0035127



## Available Sizes

**Size:** 5mg

**Size:** 10mg

**Size:** 25mg



## Specifications

**CAS No:**

926661-54-3

**Formula:**

$C_{21}H_{21}FN_2O_4S$

**Pathway:**

GPCR/G Protein

**Target:**

Prostaglandin Receptor

**Purity / Grade:**

>98%

**Solubility:**

10 mM in DMSO

**Alternative Names:**

Ramatroban analog

**Observed Molecular Weight:**


416.47

## Product Description

CRTH2-IN-1 (Ramatroban analog) is a selective **prostaglandin D2 receptor DP2 (CRTH2)** antagonist with an IC<sub>50</sub> of 6 nM in a human DP2 binding assay.

IC50 & Target: IC50: 6 nM (hDP2, CRTH2), 1 μM (hDP1)<sup>[1]</sup>

***In Vitro:*** CRTH2-IN-1 (Ramatroban analog, Compound 5) is a novel prostaglandin D2 receptor DP2 (CRTH2) antagonist with an IC<sub>50</sub> of 7 nM in a human whole blood eosinophil shape change assay (hESC). CRTH2-IN-1 (Ramatroban analog) is a novel tricyclic antagonist of the prostaglandin D2 receptor DP2 (CRTH2) with efficacy in a murine model of allergic rhinitis. Human prostaglandin D1 receptor (hDP1) binding is performed using <sup>3</sup>H-PGD2 and human platelet membranes. Human thromboxane receptor (hTP) binding performed using human platelet membranes and <sup>3</sup>H-SQ-29,548. Human prostacyclin receptor (hIP) binding performed using hIP/293 membranes and <sup>3</sup>Hiloprost. CRTH2-IN-1 inhibits hDP1 binding with an IC<sub>50</sub> of 1μM. CRTH2-IN-1 inhibits hTP and hIP binding with IC<sub>50</sub>s of >100 μM. CRTH2-IN-1 inhibits human CYP isoforms CYP3A4, CYP 2C9 and CYP2D6 with IC<sub>50</sub>s of 7, 5 and >30 μM, respectively<sup>[1]</sup>.



All products are for RESEARCH USE ONLY. Not for diagnostic & therapeutic purposes!